Nov 1, 2019 · Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4). Chromatin immunoprecipitation studies demonstrated that MYCN occupies the PA2G4 gene promoter, stimulating transcription.

Mar 17, 2023 · In neuroblastoma cells, PA2G4 is a transactivation target for MYCN. PA2G4 directly binds to and stabilises MYCN by preventing its ubiquitin-mediated proteolysis . Inhibition of PA2G4 and MYCN binding by WS6 can reduce levels of both proteins and neuroblastoma tumorigenicity in vitro and in vivo.

Mar 17, 2023 · MYCN is a major oncogenic driver for neuroblastoma tumorigenesis, yet there are no direct MYCN inhibitors. We have previously identified PA2G4 as a direct protein-binding partner of MYCN and drive neuroblastoma tumorigenesis.

Nov 1, 2019 · Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4). Chromatin immunoprecipitation studies demonstrated that MYCN occupies the PA2G4 gene promoter, stimulating transcription.

Our studies revealed that PA2G4 was able to bind directly to MYCN, leading to an oncogenic forward feedback loop of high expression levels of PA2G4-p48 and MYCN proteins . PA2G4-p48 has also been implicated in the tumorigenesis of oral squamous cell carcinoma (OSCC).

We have identified a protein called PA2G4, which is a cofactor for MYCN in promoting cancer cell growth. We have developed a compound WS6 and its analogous, which inhibits PA2G4 and MYCN protein levels and reduces tumour cell growth.

Sep 9, 2019 · Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4). Chromatin immunoprecipitation studies demonstrated that MYCN occupies the...

Sep 9, 2019 · Treated tumors showed reduced levels of both MYCN and PA2G4. Our findings demonstrate a critical role for PA2G4 as cofactor in MYCN-driven neuroblastoma and highlight competitive inhibition of the PA2G4-MYCN protein binding as …

To expand our understanding of how small molecules interfere with MYCN, we have now analyzed the direct binding of 10058-F4, as well as three of its analogs; #474, #764 and 10058 …

Feb 8, 2021 · Co-immunoprecipitation results show that a MYCN deletion mutant (AA82–254) binds strongly to PA2G4, and further studies show that a 14 AA MYCN oligopeptide (AA246–259) sequence contributes to this protein-protein interaction .